ATE378065T1 - Gastrin kompositionen, zusamemsetzungen, und deren anwendungen und zubereitung - Google Patents

Gastrin kompositionen, zusamemsetzungen, und deren anwendungen und zubereitung

Info

Publication number
ATE378065T1
ATE378065T1 AT03778179T AT03778179T ATE378065T1 AT E378065 T1 ATE378065 T1 AT E378065T1 AT 03778179 T AT03778179 T AT 03778179T AT 03778179 T AT03778179 T AT 03778179T AT E378065 T1 ATE378065 T1 AT E378065T1
Authority
AT
Austria
Prior art keywords
seq
residues
compositions
gastrin
amino acid
Prior art date
Application number
AT03778179T
Other languages
English (en)
Inventor
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE378065T1 publication Critical patent/ATE378065T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03778179T 2002-11-21 2003-11-21 Gastrin kompositionen, zusamemsetzungen, und deren anwendungen und zubereitung ATE378065T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42810002P 2002-11-21 2002-11-21
US42856202P 2002-11-22 2002-11-22
US43059002P 2002-12-03 2002-12-03
US51993303P 2003-11-14 2003-11-14

Publications (1)

Publication Number Publication Date
ATE378065T1 true ATE378065T1 (de) 2007-11-15

Family

ID=32330051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03778179T ATE378065T1 (de) 2002-11-21 2003-11-21 Gastrin kompositionen, zusamemsetzungen, und deren anwendungen und zubereitung

Country Status (14)

Country Link
US (3) US20040266682A1 (de)
EP (3) EP1837031B1 (de)
JP (2) JP2006513719A (de)
KR (1) KR20050083933A (de)
AT (1) ATE378065T1 (de)
AU (1) AU2003285229C1 (de)
BR (1) BR0316489A (de)
CA (1) CA2505167A1 (de)
DE (1) DE60317554T2 (de)
DK (1) DK1565212T3 (de)
MX (1) MXPA05005330A (de)
NO (1) NO20053027L (de)
PL (1) PL376622A1 (de)
WO (1) WO2004045640A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
CA2441228A1 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en) * 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
EP1837031B1 (de) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
DE60329724D1 (de) 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
WO2004088326A2 (en) * 2003-03-28 2004-10-14 Aphton Corporation Gastrin hormone immunoassays
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
WO2005072045A2 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
EP1765873A4 (de) * 2004-07-01 2009-07-01 Waratah Pharmaceuticals Inc Verfahren und zusammensetzungen unter anwendung von cd3-agonisten
DK1794586T3 (da) 2004-09-22 2013-05-13 Cancer Advances Inc Monoklonale antistoffer til progastrin
CN101365476A (zh) * 2005-10-07 2009-02-11 瓦拉塔药品公司 Dpp-iv抑制剂和胃泌素化合物的联合使用
EP2185181A2 (de) * 2007-09-11 2010-05-19 Mondobiotech Laboratories AG Therapeutische verwendung von gastrin-1 und g-pen-grgdspca
EP2197472A2 (de) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Verwendung von band 3 protein und pacap-27 als therapeutisches mittel
CN102378576A (zh) * 2009-04-03 2012-03-14 托里度大学 作为药物平台的具有至少一个受保护硫醇区域的peg-白蛋白组合物
KR101286721B1 (ko) 2009-06-05 2013-07-16 한국과학기술연구원 폴리-시스테인 펩티드 융합 재조합 알부민 및 이의 제조방법
EP2560675A1 (de) * 2010-04-20 2013-02-27 Novo Nordisk A/S Lang wirksame gastrinderivate
CN107129538B (zh) 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
CN102260868A (zh) * 2011-07-22 2011-11-30 上海交通大学 高耐蚀性钝化液及其生产工艺
TW201326194A (zh) * 2011-11-03 2013-07-01 Zealand Pharma As Ｇｌｐ－１胃泌素受體促效劑肽結合物
CA2867593A1 (en) * 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c-1 inhibitors
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
EP3551651B1 (de) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylierte glp-1/glp-2 duale agoniste
EP3624841A4 (de) 2017-06-15 2021-01-27 Cancer Advances, Inc., Zusammensetzungen und verfahren zur induzierung humoraler und zellulärer immunitäten gegen tumore und krebs
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
US11358994B2 (en) * 2017-07-27 2022-06-14 Saint Louis University Fatty acid modified human epidermal growth factor
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
US20230407265A1 (en) * 2022-05-20 2023-12-21 City Of Hope Composition and methods for 3d culture of islet cells

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464363A (en) 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
JPS6028994A (ja) 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
US4686283A (en) 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
EP0284898A3 (de) 1987-04-02 1990-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene
US5023077A (en) 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
DK0380230T3 (da) * 1989-01-24 1995-01-16 Aphton Corp Immunogene sammensætninger mod gastrin-peptider
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
IE68593B1 (en) 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
JP3417558B2 (ja) 1991-05-10 2003-06-16 ジェネンテク，インコーポレイテッド 配位子作用薬および拮抗薬の選択
WO1993003757A1 (en) 1991-08-16 1993-03-04 Chiron Corporation Muteins of epidermal growth factor exhibiting enhanced binding at low ph
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6558952B1 (en) 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
EP1132091A1 (de) * 1994-01-24 2001-09-12 The General Hospital Corporation Behandlung von Diabetes
WO1995029690A1 (en) 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
DE19514087A1 (de) 1995-04-13 1996-10-17 Deutsches Krebsforsch Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
WO1999045026A1 (en) 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US20040037818A1 (en) 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
EP1131350A4 (de) 1998-11-19 2005-05-04 Millennium Pharm Inc Egf-ähnliche nukleinsäuren und polypeptide und deren anwendungen
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
CA2392615A1 (en) 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
US6967100B2 (en) 2000-02-18 2005-11-22 The Walter And Eliza Hall Institute Of Medical Research Pancreatic islet cell growth factors
CN1454214A (zh) 2000-08-02 2003-11-05 赛莱技术公司 具有增高功效的修饰生物肽
CN1486204A (zh) 2001-01-12 2004-03-31 ������˹ҩƷ��˾ 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物
CA2442177A1 (en) 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
CN1169827C (zh) 2001-08-07 2004-10-06 沈阳三生制药股份有限公司 一种增强多肽在体内稳定性药物的生产方法及其应用
US7037504B2 (en) 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
IL165242A0 (en) 2002-05-24 2005-12-18 Waratah Pharmaceuticals Inc Treatment for diabetes
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
EP1837031B1 (de) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
US20040229810A1 (en) 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
AU2003283004A1 (en) 2002-10-22 2004-05-13 Waratah Pharmaceuticals, Inc. Treatment of diabetes
WO2004096853A1 (en) 2003-04-30 2004-11-11 Waratah Pharmaceuticals, Inc. Combined use of keratinocyte growth factor agonists and gastrin compounds
CN1829528A (zh) 2003-05-27 2006-09-06 瓦拉塔药品公司 包含胃泌素化合物的组合物及其在糖尿病中的应用
WO2005072045A2 (en) 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
EP1765873A4 (de) 2004-07-01 2009-07-01 Waratah Pharmaceuticals Inc Verfahren und zusammensetzungen unter anwendung von cd3-agonisten
CN101365476A (zh) 2005-10-07 2009-02-11 瓦拉塔药品公司 Dpp-iv抑制剂和胃泌素化合物的联合使用
EP1971363A1 (de) 2005-12-02 2008-09-24 Waratah Pharmaceuticals, Inc. Kombinationsbehandlungen mit gastrin-agonisten für diabetes und verwandten erkrankungen
WO2007095737A1 (en) 2006-02-21 2007-08-30 Waratah Pharmaceuticals Inc. Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound

Also Published As

Publication number Publication date
US7803766B2 (en) 2010-09-28
AU2003285229B2 (en) 2009-07-30
US20090075873A1 (en) 2009-03-19
CA2505167A1 (en) 2004-06-03
PL376622A1 (pl) 2006-01-09
US20110034379A1 (en) 2011-02-10
EP1565212A1 (de) 2005-08-24
NO20053027D0 (no) 2005-06-20
KR20050083933A (ko) 2005-08-26
BR0316489A (pt) 2005-10-11
EP1837031B1 (de) 2009-10-14
DE60317554T2 (de) 2008-09-18
EP1565212B1 (de) 2007-11-14
EP1884247A2 (de) 2008-02-06
AU2003285229C1 (en) 2010-04-01
DK1565212T3 (da) 2008-02-25
EP1837031A1 (de) 2007-09-26
EP1884247A3 (de) 2008-02-13
DE60317554D1 (de) 2007-12-27
AU2003285229A1 (en) 2004-06-15
NO20053027L (no) 2005-08-22
JP2010265294A (ja) 2010-11-25
WO2004045640A1 (en) 2004-06-03
US20040266682A1 (en) 2004-12-30
MXPA05005330A (es) 2005-10-26
JP2006513719A (ja) 2006-04-27

Similar Documents

Publication Publication Date Title
DE60317554D1 (de) Gastrin kompositionen, zusamemsetzungen, und deren anwendungen und zubereitung
Schlesinger et al. Molecular conservation of 74 amino acid sequence of ubiquitin between cattle and man
CY1112228T1 (el) Τροποποιημενο πολυπεπτιδιο επικρατειας kunitz
BRPI0511421A (pt) composições cosmética e farmacêutica para tratar materiais contendo queratina, uso de composições cosméticas, molécula efetora que liga queratina, uso da mesma, e, processo
DK2162462T3 (da) Cxc-chemokin-receptor-4 (cxcr4) antagonistisk polypeptid
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
DK165988B (da) Modificerede egliner b og c, deres anvendelse som proteaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende de modificerede egliner b og c
Soler et al. Complete amino acid sequence of the B chain of mistletoe lectin I
JP6811190B2 (ja) プロテアーゼ耐性脂質付加ｇｌｐ−１類似体
CA2439598C (en) Modified derivatives of cck-8
Franciskovich et al. A systematic evaluation of the inhibition of HIV-1 protease by its C-and N-terminal peptides
Łęgowska et al. Peptomeric analogues of trypsin inhibitor SFTI-1 isolated from sunflower seeds
Miura et al. Isolation and amino acid sequences of two trypsin inhibitors from the seeds of bitter gourd (Momordica charantia)
ATE291033T1 (de) Therapeutische peptide
Pimenta et al. Covalent structure and some pharmacological features of native and cleaved α‐KTx12− 1, a four disulfide‐bridged toxin from Tityus serrulatus venom
Seyer et al. Covalent structure of collagen: Amino acid sequence of three cyanogen bromide-derived peptides from human α1 (V) collagen chain
Terada et al. Amino acid sequences of Kunitz family subtilisin inhibitors from seeds of Canavalia lineata
WO2002083729A3 (en) Polypeptides derived from amyloid precursor peptide (app) and their uses
Tachibana et al. Isolation of dynorphin-like peptide from gut extract
ATE425988T1 (de) Peptide mit affinitat fur ein phospholipid und deren verwendung
EP0888383A1 (de) Von reaktivem c-protein abgeleitete peptide mit antientzündlichen eigenschaften
PT959895E (pt) Peptidos que reajem a anticorpos contra um peptido de consenso da familia de proteinas cs4-cfa/i
WO1998043995A1 (en) Novel anti-hiv complexes and medicinal compositions
IL125559A (en) Anti-inflammatory peptides derived from c-reactive protein and pharmaceutical compositions comprising them
FR2787454B1 (fr) Inhibiteur de la topoisomerase ii

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties